GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Beneish M-Score

Antares Pharma (Antares Pharma) Beneish M-Score : -2.39 (As of May. 06, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.39 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Antares Pharma's Beneish M-Score or its related term are showing as below:

ATRS' s Beneish M-Score Range Over the Past 10 Years
Min: -12.68   Med: -2.39   Max: 16.68
Current: -2.39

During the past 13 years, the highest Beneish M-Score of Antares Pharma was 16.68. The lowest was -12.68. And the median was -2.39.


Antares Pharma Beneish M-Score Historical Data

The historical data trend for Antares Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Beneish M-Score Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.29 -1.67 -1.62 3.21 -2.40

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.13 3.56 3.18 -2.40 -2.39

Competitive Comparison of Antares Pharma's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Antares Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Antares Pharma's Beneish M-Score falls into.



Antares Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Antares Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.4961+0.528 * 0.9645+0.404 * 0.8161+0.892 * 1.1567+0.115 * 0.8124
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.039+4.679 * -0.100685-0.327 * 0.7347
=-2.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar22) TTM:Last Year (Mar21) TTM:
Total Receivables was $93.3 Mil.
Revenue was 41.557 + 48.73 + 48.191 + 44.978 = $183.5 Mil.
Gross Profit was 22.79 + 29.763 + 31.762 + 28.538 = $112.9 Mil.
Total Current Assets was $171.6 Mil.
Total Assets was $255.7 Mil.
Property, Plant and Equipment(Net PPE) was $30.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.9 Mil.
Selling, General, & Admin. Expense(SGA) was $76.9 Mil.
Total Current Liabilities was $55.7 Mil.
Long-Term Debt & Capital Lease Obligation was $23.0 Mil.
Net Income was -2.321 + 32.683 + 5.393 + 6.706 = $42.5 Mil.
Non Operating Income was -0.144 + 38.669 + 0.006 + -0.089 = $38.4 Mil.
Cash Flow from Operations was -4.881 + 9.492 + 18.716 + 6.433 = $29.8 Mil.
Total Receivables was $53.9 Mil.
Revenue was 42.083 + 44.133 + 40.003 + 32.384 = $158.6 Mil.
Gross Profit was 25.638 + 25.074 + 23.486 + 19.907 = $94.1 Mil.
Total Current Assets was $133.5 Mil.
Total Assets was $218.5 Mil.
Property, Plant and Equipment(Net PPE) was $28.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.0 Mil.
Selling, General, & Admin. Expense(SGA) was $63.9 Mil.
Total Current Liabilities was $72.1 Mil.
Long-Term Debt & Capital Lease Obligation was $19.4 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(93.279 / 183.456) / (53.9 / 158.603)
=0.508454 / 0.339842
=1.4961

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(94.105 / 158.603) / (112.853 / 183.456)
=0.593337 / 0.61515
=0.9645

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (171.585 + 30.226) / 255.658) / (1 - (133.518 + 28.561) / 218.457)
=0.210621 / 0.258074
=0.8161

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=183.456 / 158.603
=1.1567

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.951 / (2.951 + 28.561)) / (3.938 / (3.938 + 30.226))
=0.093647 / 0.115268
=0.8124

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(76.852 / 183.456) / (63.944 / 158.603)
=0.418912 / 0.40317
=1.039

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((22.954 + 55.729) / 255.658) / ((19.362 + 72.144) / 218.457)
=0.307767 / 0.418874
=0.7347

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(42.461 - 38.442 - 29.76) / 255.658
=-0.100685

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Antares Pharma has a M-score of -2.39 suggests that the company is unlikely to be a manipulator.


Antares Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447